Vivus Shareholder QVT Financial To Support Dissident Slate

Vivus Shareholder QVT Financial To Support Dissident Slate
Source: Made with Photoshop

QVT Financial, the third largest shareholder of VIVUS, Inc. (NASDAQ:VVUS) (FRA:VIU) plans to vote for the nine-member slate proposed by dissident investor First Manhattan Co.

Play Quizzes 4

Vivus Shareholder QVT Financial To Support Dissident Slate

QVT Financial holds about 8.3 percent stake in the pharmaceutical company.

This CTA Is The Best-Performing Hedge Fund This Year

InvestAs equity long/short hedge funds have struggled this year, managed futures funds have been able to capitalize on market volatility and generate some of the best returns in the hedge fund industry. The managed futures sector refers to funds known as commodity trading advisors, or CTAs, which generally use a proprietary trading system to trade Read More

The investment management firm First Manhattan, earlier received support from proxy advisor Institutional Shareholders Services for three of its nine proposed directors.

The recent support from QVT Financial is a great morale booster for First Manhattan’s efforts to replace VIVUS, Inc. (NASDAQ:VVUS) (FRA:VIU) directors.

First Manhattan’s Views

First Manhattan Co is Vivus’ largest shareholder with 9.9 percent stake. The investment firm seeks to take full control of the pharmaceutical company’s board with its own nominees.

In its recent letter to VIVUS, Inc. (NASDAQ:VVUS) (FRA:VIU) shareholders, the investment management firm First Manhattan Co, justified why its nominees should be elected. The investment advisory firm castigated VIVUS, Inc.’s board for having limited knowledge of finance. It also charged the company of ‘hemorrhaging cash’ and with a ‘poor commercial launch for the best obesity drug ever developed’.

Once touted as a promising therapy to fight a U.S. obesity epidemic, doctors have been slow to pick Qsymia up given the troubled past of obesity drugs. Qsymia’s side effects include heart risks and the possibility of babies being born with oral clefts when taken by women during pregnancy

Vivus Board’s Recommendation

In its letter to the shareholders, VIVUS, Inc. (NASDAQ:VVUS) (FRA:VIU) highlighted under current board’s direction, the management team developed and won FDA approval for Qsymia in 2012. Since then, the management team has worked tirelessly to increase awareness and access, the two main barriers to unlocking Qsymia’s value.

The drug maker also emphasized Vivus made significant progress in establishing obesity as a drug treatment category and broadening reimbursement coverage. Despite FMC’s disruptive efforts, the company has made meaningful progress that is positioning it to enhance stockholder value.

Changes Are Necessary

The investment firm, QVT Financial feels changes are necessary at Vivus.

Former executive vice president for global commercial operations at London-based AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN), Anthony Zook, agreed to serve as chief executive officer if First Manhattan wins the proxy vote.

VIVUS, Inc. (NASDAQ:VVUS) (FRA:VIU) annual general meeting is scheduled on July 15.

Updated on

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports
Previous article Nokia Lumia 1020 Photos Leaked Ahead Of Today’s Event
Next article How To Get iOS 7 Like Control Center on Android

No posts to display